RhumbLine Advisers
CADL icon

RhumbLine Advisers’s Candel Therapeutics CADL Stock Holding History

RhumbLine Advisers’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$252K Buy
51,399
+394
+0.8% +$2.14K ﹤0.01% 3007
2025
Q4 		$288K Sell
51,005
-2,635
-5% -$14.2K ﹤0.01% 2996
2025
Q3 		$274K Sell
53,640
-858
-2% -$4.96K ﹤0.01% 3058
2025
Q2 		$276K Buy
54,498
+21,196
+64% +$109K ﹤0.01% 3045
2025
Q1 		$188K Buy
33,302
+7,030
+27% +$57.4K ﹤0.01% 3130
2024
Q4 		$228K Buy
26,272
+3,817
+17% +$22.6K ﹤0.01% 3123
2024
Q3 		$156K Sell
22,455
-530
-2% -$3.29K ﹤0.01% 3345
2024
Q2 		$143K Buy
+22,985
New +$173K ﹤0.01% 3395

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's CADL Position: Q1 2026 in Review

RhumbLine Advisers increased its Candel Therapeutics (CADL) stake by 0.77% in Q1 2026, buying an estimated $2.14K and bringing the position to 51,399 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #3007.

RhumbLine Advisers first reported a position in CADL in Q2 2024 and has held it in 8 quarters since. The position peaked at $288K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • RhumbLine Advisers held 51,399 shares of Candel Therapeutics worth $252K as of Q1 2026.
  • RhumbLine Advisers bought 394 Candel Therapeutics shares in Q1 2026, an estimated $2.14K.
  • Candel Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3007 holding.
  • RhumbLine Advisers first reported a position in Candel Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • RhumbLine Advisers's Candel Therapeutics position peaked at $288K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.